Clinical Trials Logo

Filter by:
NCT ID: NCT03484702 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

TRANSCENDWORLD
Start date: September 7, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)

NCT ID: NCT03484065 Completed - Clinical trials for Afibrinogenemia, Congenital

Quality of Life in Patients With Congenital Afibrinogenemia

QualyAFIB
Start date: June 2016
Phase:
Study type: Observational

The aim of this observational study is to evaluate the quality of life in patients with congenital afibrinogenemia using the Haemo-QoL SF for kids and the Haem-A-QoL for adult patients.

NCT ID: NCT03482713 Completed - Chronic Cough Clinical Trials

Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)

Start date: March 16, 2018
Phase: Phase 2
Study type: Interventional

This estimation study (no hypotheses) will evaluate the safety, tolerability, and efficacy of gefapixant (MK-7264) in Japanese adult participants with unexplained or refractory chronic cough.

NCT ID: NCT03482635 Completed - Colitis, Ulcerative Clinical Trials

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

Start date: March 27, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are - to prove the concept of clinical activity of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments and to identify efficacious and safe dose regimens in Part 1 (Phase II) - to confirm efficacy and safety of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments in Part 2 (Phase III) - To provide, along with induction study 1368-0018 and the run-in cohort of 1368-0020, the target population to be evaluated in study 1368-0020.

NCT ID: NCT03482011 Completed - Psoriasis Clinical Trials

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

OASIS-1
Start date: April 24, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.

NCT ID: NCT03481634 Completed - Clinical trials for Diabetic Macular Edema

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

KESTREL
Start date: July 23, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).

NCT ID: NCT03479944 Completed - Cataract Clinical Trials

Clinical Evaluation of FLACS With Combination of LenSx® and Centurion®

Start date: August 22, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate cumulative dissipated energy (CDE), endothelial cell loss, and average torsional amplitude with combination of LenSx® and Centurion® compared to conventional cataract surgery.

NCT ID: NCT03476746 Completed - Healthy Clinical Trials

Dermatopharmacokinetic Trial of LEO 90100 Foam

Start date: March 20, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1, single centre trial in Japanese healthy male subjects comparing the amount of active ingredients of LEO 90100 foam and Dovobet® ointment in the stratum corneum.

NCT ID: NCT03475459 Completed - Clinical trials for Qt Interval, Variation in

Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7)

Start date: April 3, 2018
Phase: Phase 1
Study type: Interventional

A study to assess the QTc prolongation effect of NPC-15 (melatonin 8mg or 16mg)

NCT ID: NCT03474679 Completed - Clinical trials for Graft vs Host Disease

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

Start date: May 1, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and partial response [PR] defined by National Institutes of Health [NIH] consensus development project criteria [2014]).